Pharmacology of Pulmonary Arterial Hypertension: An Overview of Current and Emerging Therapies

Abstract

Pulmonary arterial hypertension is a rare and devastating disease characterized by an abnormal chronic increase in pulmonary arterial pressure above 20 mmHg at rest, with a poor prognosis if not treated. Currently, there is not a single fully effective therapy, even though a dozen of drugs have been developed in the last decades. Pulmonary arterial hypertension is a multifactorial disease, meaning that several molecular mechanisms are implicated in its pathology. The main molecular pathways regulating the pulmonary vasomotor toneendothelin, nitric oxide, and prostacyclinare the most biologically and therapeutically explored to date. However, drugs targeting these pathways have already found their limitations. In the last years, translational research and clinical trials have made a strong effort in suggesting and testing novel therapeutic strategies for this disease. These approaches involve targeting the main molecular pathways with novel drugs, drug repurposing for novel targets, and also using combinatorial therapies. In this review, we summarize current strategies and drugs targeting the endothelin, nitric oxide, and prostacyclin pathways, as well as, the emerging new drugs proposed to cope with vascular remodelling, metabolic switch, perivascular inflammation, epigenetic modifications, estrogen deregulation, serotonin, and other neurohumoral mechanisms characteristic of this disease. Nowadays, pulmonary arterial hypertension remains an incurable disease; however, the incoming new knowledge makes us believe that new promising therapies are coming to the clinical arena soon.

Effect of Coronavirus Disease 2019 in Pulmonary Circulation. The Particular Scenario of Precapillary Pulmonary Hypertension

“…ARDS suffer severe hypoxemia related to intrapulmonary right-to-left shunts, and specific pulmonary vasodilators are commonly used to shift the blood flow to properly ventilated areas [ 81 ]. Furthermore, these treatments have also an anti-inflammatory effect and a beneficial effect on endothelial homeostasis [ 82 ].…”

Crocin's role in modulating MMP2/TIMP1 and mitigating hypoxia-induced pulmonary hypertension in mice

“…Over the past two decades, the development of new drugs has driven innovations in PAH therapy. However, most of these therapeutic targets are focused on vasodilation, and treatment for this disease has limitations 31 . Several previous studies have shown that patients treated with these targeted drugs have high mortality rates despite significantly improved short-term outcomes.…”

Recent advances in the pharmacotherapy of pulmonary hypertension: practical considerations

“…Therapies are divided into 4 pharmacological groups according to their mechanism of action [1,8] (Table 1):…”

“…Other vasoactive strategies such as the use of aldosterone antagonist or the angiotensin II receptor antagonist have been studied. However, despite they are generally well tolerated the appearance of some systemic severe adverse effects such as hypotension, bradycardia or hypoxemia could compromise RV function and life of PAH patients [8].…”